Receptor-based virtual screening evaluation for the identification of estrogen receptor β ligands

References

• Dahlman-Wright K, Cavailles V, Fuqua SA, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006;58:773–81
   PubMed Web of Science ®Google Scholar
• Dey P, Barros RP, Warner M, et al. Insight into the mechanisms of action of estrogen receptor beta in the breast, prostate, colon, and CNS. J Mol Endocrinol 2013;51:T61–74
   PubMed Web of Science ®Google Scholar
• Harris HA. Estrogen receptor-beta: recent lessons from in vivo studies. Mol Endocrinol 2007;21:1–13
   PubMed Web of Science ®Google Scholar
• Swedenborg E, Power KA, Cai W, et al. Regulation of estrogen receptor beta activity and implications in health and disease. Cell Mol Life Sci 2009;66:3873–94
   PubMed Web of Science ®Google Scholar
• Hartman J, Strom A, Gustafsson JA. Current concepts and significance of estrogen receptor beta in prostate cancer. Steroids 2012;77:1262–6
   PubMed Web of Science ®Google Scholar
• Haring J, Schuler S, Lattrich C, et al. Role of estrogen receptor beta in gynecological cancer. Gynecol Oncol 2012;127:673–6
   PubMed Web of Science ®Google Scholar
• Treeck O, Pfeiler G, Mitter D, et al. Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 2007;193:421–33
   PubMed Web of Science ®Google Scholar
• Leygue E, Murphy LC. A bi-faceted role of estrogen receptor beta in breast cancer. Endocr Relat Cancer 2013;20:R127–39
   PubMed Web of Science ®Google Scholar
• Haldosen LA, Zhao C, Dahlman-Wright K. Estrogen receptor beta in breast cancer. Mol Cell Endocrinol 2014;382:665–72
   PubMed Web of Science ®Google Scholar
• Kumar S, Patel R, Moore S, et al. Estrogen receptor beta ligand therapy activates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes remyelination in a mouse model of multiple sclerosis. Neurobiol Dis 2013;56:131–44
   PubMed Web of Science ®Google Scholar
• Wu WF, Tan XJ, Dai YB, et al. Targeting estrogen receptor beta in microglia and T cells to treat experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2013;110:3543–8
   PubMed Web of Science ®Google Scholar
• Minutolo F, Bertini S, Granchi C, et al. Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta. J Med Chem 2009;52:858–67
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002;296:1642–4
   PubMed Web of Science ®Google Scholar
• Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor beta ligands: recent advances and biomedical applications. Med Res Rev 2011;31:364–442
   PubMed Web of Science ®Google Scholar
• Zhao L, Brinton RD. Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases. J Med Chem 2005;48:3463–6
   PubMed Web of Science ®Google Scholar
• Knox AJ, Meegan MJ, Sobolev V, et al. Target specific virtual screening: optimization of an estrogen receptor screening platform. J Med Chem 2007;50:5301–10
   PubMed Web of Science ®Google Scholar
• Shen J, Tan C, Zhang Y, et al. Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening. J Med Chem 2010;53:5361–5
   PubMed Web of Science ®Google Scholar
• Cao X, Jiang J, Zhang S, et al. Discovery of natural estrogen receptor modulators with structure-based virtual screening. Bioorg Med Chem Lett 2013;23:3329–33
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42
   PubMed Web of Science ®Google Scholar
• Maestro, version 9.0. Portland (OR): Schrödinger Inc; 2009
   Google Scholar
• Macromodel, version 9.7. Portland (OR): Schrödinger Inc; 2009
   Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91
   PubMed Web of Science ®Google Scholar
• DOCK, version 6.0. San Francisco (CA): Molecular Design Institute, University of California; 1998
   Google Scholar
• FRED, version 2.2.5. Santa Fe (NM): OpenEye Scientific Software, Inc.; 2010
   Google Scholar
• GLIDE, version 5.0. Portland (OR): Schrödinger Inc; 2009
   Google Scholar
• Verdonk ML, Mortenson PN, Hall RJ, et al. Protein-ligand docking against non-native protein conformers. J Chem Inf Model 2008;48:2214–25
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455–61
   PubMed Web of Science ®Google Scholar
• Sanner MF. Python: a programming language for software integration and development. J Mol Graph Model 1999;17:57–61
   PubMed Web of Science ®Google Scholar
• Case DA, Darden TA, Cheatham TE III, et al. AMBER, version 11. San Francisco (CA): University of California; 2010
   Google Scholar
• OMEGA2, version 2.4.6. Santa Fe (NM): OpenEye Scientific Software, Inc.; 2013
   Google Scholar
• Verdonk ML, Cole JC, Hartshorn MJ, et al. Improved protein-ligand docking using GOLD. Proteins 2003;52:609–23
   PubMed Web of Science ®Google Scholar
• Huang N, Shoichet BK, Irwin JJ. Benchmarking sets for molecular docking. J Med Chem 2006;49:6789–801
   PubMed Web of Science ®Google Scholar
• Mewshaw RE, Edsall RJ, Jr, Yang C, et al. ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem 2005;48:3953–79
   PubMed Web of Science ®Google Scholar
• Poli G, Tuccinardi T, Rizzolio F, et al. Identification of new fyn kinase inhibitors using a FLAP-based approach. J Chem Inf Model 2013;53:2538–47
   PubMed Web of Science ®Google Scholar
• SciFinder Scholar. Washington, DC: American Chemical Society; 2013
   Google Scholar
• Tuccinardi T. Docking-based virtual screening: recent developments. Comb Chem High Throughput Screen 2009;12:303–14
   PubMed Web of Science ®Google Scholar
• Wilkening RR, Ratcliffe RW, Tynebor EC, et al. The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands. Bioorg Med Chem Lett 2006;16:3489–94
   PubMed Web of Science ®Google Scholar
• Bey E, Marchais-Oberwinkler S, Werth R, et al. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). J Med Chem 2008;51:6725–39
   PubMed Web of Science ®Google Scholar
• Bey E, Marchais-Oberwinkler S, Negri M, et al. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. J Med Chem 2009;52:6724–43
   PubMed Web of Science ®Google Scholar
• Suetsugi M, Su L, Karlsberg K, et al. Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res 2003;1:981–91
   PubMed Web of Science ®Google Scholar
• Barlaam BD, Steven FJ. Preparation of benzimidazoles as selective estrogen receptor-b ligand. Patent WO2002046168;2002
   Google Scholar